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Abstract
Background: Based on our preclinical findings, we are assessing the efficacy of intratumoral injection of dendritic cells (DC)
transduced with an adenoviral vector expressing the secondary lymphoid chemokine (CCL21) gene (Ad-CCL21-DC) in a
phase I trial in advanced non-small cell lung cancer (NSCLC). While this approach shows immune enhancement, the
preparation of autologous DC for CCL21 genetic modification is cumbersome, expensive and time consuming. We are
evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery to mediate
antitumor activity in lung cancer.
Principal Findings: Here we describe that vault nanocapsule platform for CCL21 delivery elicits antitumor activity with
inhibition of lung cancer growth. Vault nanocapsule packaged CCL21 (CCL21-vaults) demonstrated functional activity in
chemotactic and antigen presenting activity assays. Recombinant vaults impacted chemotactic migration of T cells and this
effect was predominantly CCL21 dependent as CCL21 neutralization abrogated the CCL21 mediated enhancement in
chemotaxis. Intratumoral administration of CCL21-vaults in mice bearing lung cancer enhanced leukocytic infiltrates
(CXCR3
+T, CCR7
+T, IFNc
+T lymphocytes, DEC205
+ DC), inhibited lung cancer tumor growth and reduced the frequencies of
immune suppressive cells [myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), IL-10 T cells]. CCL21-vaults
induced systemic antitumor responses by augmenting splenic T cell lytic activity against parental tumor cells.
Significance: This study demonstrates that the vault nanocapsule can efficiently deliver CCL21 to sustain antitumor activity
and inhibit lung cancer growth. The vault nanocapsule can serve as an ‘‘off the shelf’’ approach to deliver antitumor
cytokines to treat a broad range of malignancies.
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Introduction
Lung cancer is the leading cause of cancer death in the United
States and worldwide [1]. To date with the existing forms of
therapy, the overall long term survival is only 15%. Thus, new
therapeutic strategies are needed. We are evaluating a novel vault
nanocapsule as a proof of concept for the delivery of immune
potentiating cytokines for an ‘‘off the shelf reagent’’ for immune
based therapy for lung cancer.
Vaults are cytoplasmic ubiquitous ribonucleoprotein particles
first described in 1986 [2]. Native vaults are 12.961 MDa ovoid
spheres with overall dimensions of approximately 40 nm in width
and 70 nm in length [3,4], present in nearly all-eukaryotic
organisms with between 10
4 and 10
7 particles per cell [5]. Despite
their cellular abundance, vault function remains elusive although
they have been linked to many cellular processes including the
innate immune response, multidrug resistance in cancer cells,
multifaceted signaling pathways, and intracellular transport [6].
As a naturally occurring nanocapsule, the vault particle may be
an ideal structure to engineer as a therapeutic system for
compound encapsulation, protection, and delivery. Vaults are
highly stable structures in vitro, and a number of studies indicate
that the particles are non-immunogenic [7]. Vaults can be
engineered and expressed using a baculovirus expression system
and heterologous proteins can be encapsulated inside of these
recombinant particles using a protein-targeting domain termed
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been fused to the INT domain (e.g. fluorescent and enzymatic
proteins) and these fusion proteins when packaged into the
recombinant vaults, retain their native characteristics, and thus
confer new vault properties [8,9].
CCL21 has been identified as a lymphoid chemokine that is
predominantly and constitutively expressed by high endothelial
venules in lymph nodes and Peyer’s patches, lymphatic vessels and
stromal cells in spleen and appendix [10]. CCL21 binds to the
chemokine receptor CCR7 and is a chemoattractant for mature
dendritic cells (DC), naive and memory T cells [11,12]. This
chemokine, along with CCL19, is required for normal lymphoid
tissue organization that is ultimately essential for effective T cell-DC
interactions. Natural killer (NK) and natural killer T (NKT)
antitumor effectors also express CCR7 receptor and are chemo
attracted by CCL21. The use of chemokines to attract DC,
lymphocyte, NK and NKT effectors into tumors can serve as an
effective antitumor strategy. Based on this concept, we have
previously shown that intratumoral administration of recombinant
CCL21 reduces tumor burden in murine lung cancer models [13].
The antitumor activity induced by recombinant CCL21 however
required high and frequent dosing because proteins administered
intratumorally are not retained locally for prolonged periods.
Although these studies delineated the role of CCL21 as an effective
antitumor agent, frequent high dose intratumoral administration is
clinicallylimiting with the potentialof unnecessary systemic toxicity.
Based on the limitations of this approach, we examined the use of
DC for intratumoral CCL21 delivery [14,15]. In preclinical studies
we demonstrated that intratumoral administration of CCL21 gene
modified DC led to tumor eradication in murine lung cancer
models. Following our initial description of the antitumor activities
of CCL21, several groups have reported that CCL21 has potent
antitumor properties in a variety of model systems [16,17,18,19,20].
In all models, CCL21 demonstrated potent regression of tumors,
which was shown to be dependent on host T cell immunity.
Based on extensive pre-clinical evaluation, we began an NCI
funded clinical trial one year ago assessing the intratumoral
injection of DC transduced with an adenoviral vector expressing
the CCL21 gene (Ad-CCL21-DC) in a phase I trial in advanced
non-small cell lung cancer (NSCLC) [21]. While our clinical
studies utilizing intratumoral administration of CCL21 gene
modified DC shows immune enhancement, the preparation of
CCL21 expressing autologous DC is cumbersome, expensive and
time consuming. An efficacious off-the-shelf reagent would
facilitate the evaluation of this chemokine-based therapy. Towards
achieving this goal, we are evaluating a non-DC based approach
which utilizes vault nanoparticles for intratumoral CCL21 delivery
for the purpose of initiating antitumor immune responses in lung
cancer. We anticipate that the use of vault nanoparticles will
circumvent autologous DC preparation, minimize batch to batch
variability and allow for comparability and standardization. In
addition, vault nanoparticles engineered to release CCL21 can be
used to treat a broad range of malignancies.
In this study we evaluated the effect of vault nanocapsule delivery
of CCL21 on the growth of Lewis Lung (3LL) tumors
in vivo. Our findings indicate that a single intratumoral administra-
tion of CCL21-vault nanocapsules recruits antitumor effectors,
induces potent antitumor activity and inhibits tumor growth.
Materials and Methods
Recombinant Vaults
The CCL21 cDNA was fused in frame to either INT or
mCherry-INT [22]. Murine CCL21 was PCR amplified with the
primers: CCL21- forward GCGCGGATCCCCATGGCTCA-
GATGATG and CCL21- reverse GCGCAGATCTTCCTCTT-
GAGGGCTGTGTCTG. To form mCCL21-mCherry-INT in
pFastBac, purified CCL21 PCR product was digested with
BamH1 and Bgl I and ligated to BamH1 phosphatase treated
mCherry-INT pFastBac. Human CCL21 was PCR amplified with
the primers: CCL-21 F-SpeI CCCCACTAGTC CAGTTCT-
CAGTCACTGGCTCTG, CCL-21-NheI CCCCGCTAGCTG-
GCCCTTTAGGGGTCTGTG, INT with NheI CCCCGCT-
AGCTGCACACAACACTGGCAGGA, INT with XhoI GGGG-
CTCGAGTTAGCCTTGACTGTAATGGA to form hCCL21-
INT. Recombinant (r) baculoviruses were generated as described
[7]. Sf9 cells were infected with mCCL21-mCherry-INT,
hCCL21-INT or CP-MVP encoding baculoviruses at a multiplic-
ity of infection (MOI) of 0.01 for 65 h. The infected cells were
prepared as described [7]. Lysates containing CP-MVP vault were
mixed with lysates containing mCCL21-mCherry-INT or
hCCL21-INT and were incubated on ice for 30 min to allow
the INT fusion proteins to package inside of vaults. Vault were
purified as described [8], resuspended in sterile PBS and protein
concentration determined by BCA assay (Bio-Rad, CA). Sample
integrity was analyzed by negative stain electron microscopy or
Coomassie staining of SDS-PAGE followed by Western blot
analysis. CCL21-INT protein in the vault was quantified by
densitometric analysis of Western blots against purified recombi-
nant INT protein as standard.
Antibodies
Primary antibodies for western blot analyses were rabbit anti-
MVP antibody (1/1000 dilution) [23] or rabbit anti-VPARP
antibody (1/500 dilution) [24] and secondary goat anti-rabbit
HRP-antibody (1:2000 dilution) (Amersham). The CCL21 and
CXCR3 (220803) mAb were from R&D, (Minneapolis, MN),
primary immunostaining CD3 mAb was from DAKO (Cytoma-
tion, Carpinteria, CA, USA). FlTC, PE, APC, PerCP or PerCP-
Cy7-conjugated anti-mouse mAbs to CD3 (145-2C11), CD4
(RM4-5), CD8a (53-6.7) and isotype control antibody were from
BD Biosciences (San Diego, CA), mAbs to detect Tregs with CD4
(GK1.5), CD25 (PC61), intranuclear Foxp3 (FJK-16s) IL-10
(JES5-16E3), IFNc (XMG1.2), DEC205 (205yekta), CCR7
(4B12) and EpCam (G8.8) were from eBioScience(San Diego,
CA), mAb CD11b (M1/70), Gr1 (RB6-8C5), were from
BioLegend (San Diego). Bradford protein quantification dye was
from Sigma.
Chemotaxis assay
Chemotaxis assays were performed using 24-well plates with
3 mm pore size inserts (Costar/Corning, Corning, New York)
according to the manufacturer’s instructions. 2.0610
5 T2 cells in
serum-free medium were loaded in the upper chamber. 200 ng/
ml of CCL21-mcherry-INT/vault, 600 ng/ml rCCL21 (R&D),
200 ng/ml CCL21-mCherry-INT/CP-MVP vault with neutraliz-
ing CCL21 antibody (5 mg/ml), 600 ng/ml CCL21 with CCL21
antibody (5 mg/ml) were added to the lower chambers. After 2 hr
incubation, migrated cells were enumerated by FACS.
Antigen processing and presentation assay
DC2.4 (5610
4c/well) were plated in 96-well plates with OVA
protein (350 mg/ml), CD8 T cell line B3Z (10
5c/well), in the
presence of control vaults (200 ng/ml), or mCCL21-vaults
(200 ng/ml) or rCCL21 (200 ng/ml) for 24 hrs. To determine
the impact of CCL21 on APC activity, CCL21 was neutralized
with anti-CCL21 Ab (5 mg/ml). IL-2 secreted by activated CD8 T
cells was quantified by ELISA (eBioScience).
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The Lewis lung carcinoma cell line (3LL) was obtained from
ATCC (Manassas, VA) and was cultured as described [25]. The cell
line was mycoplasma free and utilized before the tenth passage.
Tumorigenesis Model
Pathogen-free C57BL/6 mice or UBC-GFP/BL6 (6–8 wk old;
Jackson Laboratory) were maintained in the Veterans Affairs Animal
Research vivarium in accord with the institution’s animal review
board guidelines. All animal work was conducted in accord with the
Veterans Affairs Institutional Animal care and Use Committee
guidelines: id A3002-01. The institutional review board approved all
the studies involving animals in this manuscript. Animals exhibiting
signs of pain or meeting the endpoint criteria were euthanized
immediately according to the accepted institution based protocol.
3LL tumor cells (1.5610
5) were injected s.c. in the right suprascapular
area of mice. Mice bearing 9-day-old established tumors weretreated
with a single intratumoral injection of mCCL21-mCherry-INT/CP-
MVP vaults (200 ng), CP- MVP vaults (200 ng) in 200 mlo rN S
diluents.Tumor volumes weremonitored and calculated as described
[25]. To determine the lymphocytes infiltrating the tumors, UBC-
GFP/BL6 mice bearing 9-day tumors were treated and 7 days post
treatment, non-necrotic tumors were isolated and frozen in OCT.
The frozen tissue was sectioned, fixed and counterstained with 49,6-
diamidino-2-phenylindole (DAPI) and observed under a 1671
Olympus fluorescence microscope. The images were acquired using
the Image Pro software.
Orthotopic model
3LL-GFP cells (5610
3) were implanted in the left lung as
described [25]. One week following tumor inoculation, mice were
treated with diluent, control vaults or mCCL21-vaults via
transthoracic injection. Four weeks after tumor implantation,
lungs were harvested for evaluation of tumor burden and
leukocytic infiltrates as described [25].
Immunostaining
Tumors section were prepared according to standard protocol
[26]. Slides were incubated with primary antibody (CD3 1:200)
overnight at 4uC, washed and incubated with secondary biotiny-
lated. The slides were developed with Vectastain ABC-AP kit and
Vector Red substrate solution (Vector Laboratories, Burlingame,
California). Slides were counterstained with hematoxylin.
Flow Cytometry
FACs analyses was performed for CD3, CD4, CD8, CCR7,
CD11b, Gr1, DEC205, CD25, FOXP3, CXCR3 and intracyto-
plasmic T cell IFNc and IL-10 on a single lung tumor cell
suspension as described [25].
T cell Cytolysis
Splenic T lymphocyte lysis was evaluated against autologous
3LL and control B16 melanoma cells as described [25].
Statistical analysis
Statistical analyses were performed using t-tests or Mann-Whitney
tests. All statistical analyses were done at GraphPad PRISM 5 software.
Results
Packaging CCL21 into recombinant vaults
Several exogenous proteins have been packaged inside of
recombinant vaults (luciferase, green fluorescent protein,
mCherry fluorescent protein, adenovirus protein VI, and the
major outer membrane protein of Chlamydia) when fused to a
162 amino acids vault-targeting domain (INT) derived from the
vault-associated protein (VPARP, amino acids 1563–1724).
These fusion proteins bind with high affinity to the interior of
the vault particle, are protected from the external environment,
and retain their native properties, thus conferring new charac-
teristics onto the recombinant vault particles [7,9,22]. The mouse
chemokine CCL21 was fused to INT to create a CCL21 fusion
protein (mCCL21-INT) that can be packaged inside of
recombinant vaults. Mixing of lysates containing recombinant
CCL21-INT and rat MVP generated in Sf-9 cells allowed the
formation of a macromolecular vault complex containing the
CCL21 fusion protein that could be isolated by density gradient
ultracentrifugation. The purified vaults contained both MVP as
well as CCL21-INT (henceforth referred to as CCL21-vaults) as
indicated by Coomassie staining and immunoblot analyses
(Fig. 1). For these studies three different vaults were prepared.
One was packaged with mouse CCL21 fused to the fluorescent
protein mCherry-INT (mCCL21-mCherry-INT/CP-MVP vaults,
abbreviated here mCCL21-vaults), a second vault was packaged
with human CCL21-INT (hCCL21-INT/CP-MVP vaults, ab-
breviated here hCCL21-vaults) and the third was a control empty
vault (CP-MVP vaults [27]) (Fig. 1A and B). We estimated the
amount of CCL21 packaged inside the vaults by quantitative
Western blots. Our analysis indicated that 20–30 molecules of the
CCL21-INT protein were packaged in each CCL21-vault
particle. This is consistent with our previous experience in
packaging multiple copies of other INT fusion proteins into
recombinant vaults [22]. With an estimate of 20–30 CCL21-INT
proteins per vault, it is likely that this is at or near a saturating
level for the packaging of this size protein. The CCL21-vaults
Figure 1. Evaluation of recombinant CCL21-vaults. A. Coomassie
stain of purified vaults fractionated on a 4–16% SDS-PAGE. Lane 1,
molecular weight markers. Lane 2, mCCL21-mCherry-INT/CP-MVP
vaults. The 97-kDa MVP band is indicated by the arrow. Lane 3,
hCCL21-INT/CP-MVP vaults. Lane 4, CP-MVP vaults. B. Western blot
analyses of purified vaults to confirm the presences of MVP or the
indicated INT fusion proteins (arrows). Lane 1, mCCL21-mCherry-INT/
CP-MVP vaults were immunoblotted with anti-MVP antibody. Lane 2,
mCCL21-mCherry-INT/CP-MVP vaults were immunoblotted with anti-
INT antibody. Lane 3, hCCL21-INT/CP-MVP vaults were immunoblotted
with anti-INT antibody. C. Negative-stained electron micrographs of
purified vaults. CP-MVP vaults (left), mCCL21-mCherry-INT/CP-MVP
vaults (center), hCCL21-INT/CP-MVP vaults (right).
doi:10.1371/journal.pone.0018758.g001
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gradients as vault particles containing the INT domain fused to
luciferase, [7,9,22] suggesting that incorporation of CCL21-INT
did not impact the normal structure of recombinant vault
particles. To verify this, we examined purified vault complexes
by negative stain transmission electron microscopy (Fig. 1C). The
CCL21-vaults exhibited the characteristic barrel shaped mor-
phology of vaults, consistent with the previously established
morphology of vaults containing recombinant-INT fusion
proteins [9,27].
CCL21-vaults are biologically active and induce the
migration of T2 cells and enhance DC APC activity
A chemotaxis assay was used to determine if CCL21 retains
biological function when packaged in the recombinant vaults.
The chemotactic activity of CCL21 is mediated through its
receptor CCR7 to induce the migration of T cells and DC. To
evaluate the biological activity of CCL21 in the vault, we used T2
hybridoma cells that constitutively express CCR7. Two different
concentrations of CCL21-vaults (200 ng and 600 ng), empty
vaults (600 ng), and recombinant CCL21 (600 ng) were placed in
the bottom chamber of a 24-well transwell plates and 2610
5 T2
cells were added to the upper chamber. The number of cells that
migrated to the lower chamber was determined by flow
cytometry and represented as % migration (Fig. 2A). More than
7.5% of the T2 cells responded to 200 ng of mCCL21-vaults
compared with #2.5% of the T2 cells incubated with 600 ng of
recombinant CCL21. This is a potent response considering that
the concentration noted above is for CCL21-vaults and the actual
concentration of CCL21 in the vaults is estimated to be #20 ng.
The increased bioactivity of mCCL21-vaults may be due to
increased stabilization of CCL21 resulting from packaging of the
protein into the protective environment of the vault lumen. As
the fusion protein non-covalently associates within vaults, the
vault breathing in solution may release CCL21 in a gradient
fashion. Thus the number of cells migrating in response to
mCCL21-vaults was higher than the recombinant CCL21
because a steeper gradient is formed. To determine if the
migration of T2 cells was CCL21-dependent, an anti-CCL21
neutralizing antibody was utilized to block the chemotactic
activity of both recombinant CCL21 and mCCL21-vaults. The
anti-CCL21 blocked mCCL21-vault functional activity indicating
chemotactic activity in a CCL21 specific manner (Fig. 2A). The
impact of mCCL21-vaults on DC APC activity was evaluated
in vitro. In comparison to control vaults, mCCL21-vaults
augmented DC capacity to process and present ovalbumin and
activate CD8 T cells to secrete IL-2. Neutralization of CCL21
abrogated the increase in DC APC activity to control levels
(Fig. 2B). Similar results were observed with hCCL21-vaults on
DC APC activity (data not shown).
CCL21-vaults enhance the recruitment of leukocytic
infiltrates and inhibit 3LL tumor growth
We determined the antitumor activity of mCCL21-vaults on
established 3LL tumor in vivo. A single intratumoral injection of
mCCL21-vaults (200 ng) led to significant decrease in tumor
Figure 2. CCL21-vaults enhance the chemotactic migration of T cells and DC APC activity. A. CCL21-vaults increased the migration of T2
cells. 2.0610
5 T2 cells were plated in serum-free medium in the upper chamber. mCCL21-mCherry-INT/CP-MVP vaults (200 ng/ml or 600 ng/ml),
recombinant CCL21 (600 ng/ml), control vaults (CP-MVP vaults 600 ng/ml) or neutralizing anti-CCL21 recombinant antibody (5 mg/ml) were added to
the lower chamber of the wells. Following 2 hr incubation, migration of T2 cells were analyzed by flow cytometry. mCCL21-vaults effectively
increased the T2 migration as compared with control. Anti-CCL21 neutralizing Ab to CCL21 abrogated the increase in T2 migration suggesting that
CCL21 in the vault predominantly mediate the chemotatic migration of T2 cells. Data in the panel are representative of 2 independent experiments.
Bars; Mean 6 SEM, *p,0.05 between the mCCL21-vaults and control vaults or anti-CCL21 antibody treatment groups. B. mCCL21-vaults enhanced
DC APC activity and blocking CCL21 reversed the increase in APC activity. B3Z cells (1610
5 cells/200 ml/well) were co-cultured with DC 2.4 (5610
4
cells/200 ml/well) and ovalbumin (350 mg/ml) in the presence or absence of mCCL21-vaults (200 ng/ml) and anti-CCL21 antibody (5 mg/ml) or control
antibody (5 mg/ml goat IgG) for 24 hrs. Control vaults were used at a concentration of 200 ng/ml. T cell activation status was measured by IL-2
production by ELISA. Data are representative of 2 independent experiments. Bars; Mean 6 SEM, *p,0.05 between the mCCL21-vaults and control
vaults or anti-CCL21 antibody treatment groups.
doi:10.1371/journal.pone.0018758.g002
CCL21-Vault Immune Therapy for Lung Cancer
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e18758growth compared to empty vaults (Fig. 3A). The mCCL21-vault
treatment group showed enhanced intratumoral leukocytic
infiltrates compared to control vaults (Fig. 3B) and immune
staining demonstrated that the infiltrates were predominantly
CD3 expressing T cells (Fig. 3C bottom right panel). The
antitumor efficacy of mCCL21-vaults was determined in the 7-
day established orthotopic 3LL lung cancer model. mCCL21-
vaults inhibited tumor burden by 7-fold compared to controls
(Fig. 4A–B). In the control treatment groups (diluents or control
vault), there were 7–9% decrease in the average body weight at
the end of the experimental duration but no significant weight
change was observed in the CCL21-vault treatment group. An
evaluation of intratumoral leukocytic populations showed
enhanced frequency of CD4, CD8, CD3 CXCR3, CD3 CCR7
and DEC205 but reduced frequency of MDSC and Tregs
(Fig. 4C).
CCL21-vaults increase tumor infiltrating T cells with
enhanced IFNc but reduced IL-10 and augment systemic
T cell cytolytic activity
Tumor T lymphocytic infiltrates from mCCL21-vault treated
mice had increased intracytoplasmic IFNc and reduced IL-10
(Fig. 4D–E). Intratumoral mCCL21-vaults induced systemic
antitumor immune activity: splenic T cells from mCCL21-vault
treated mice had augmented lytic activity against parental tumor
cells in vitro (Fig. 4F).
Discussion
We have previously shown that intratumoral recombinant
CCL21 or CCL21 gene modified DC induce a T cell dependent
tumor reduction in murine models of lung cancer [13,14,
15,28,29]. Based on extensive preclinical modeling, we have
translated our intratumoral DC-AdCCL21 approach to treat
advanced stage lung cancer in a phase I clinical trial. Although the
initial results of this trial suggest immune enhancement, we are
evaluating CCL21 delivery mechanisms that will obviate the need
to isolate and culture autologous DC. To this end we evaluated
CCL21-vault nanocapsules as an ‘‘off the shelf’’ therapeutic
platform against tumor growth in vivo utilizing the well character-
ized 3LL cancer model. Our rationale for administration of
intratumoral CCL21-vault nanocapsules is to promote the
recruitment of T lymphocytes and DC into the tumor microen-
vironment for a robust antitumor activity.
As a naturally-occurring, non-immunogenic, protein-based
nanoscale capsule, the vault particle has the potential to serve as
a flexible therapeutic delivery vehicle. Engineered in the
baculovirus system, the particle self-assembles from a single
expressed protein which can be modified to allow cell targeting,
specific endocytosis and endosome penetration [7,8,9,30]. Proteins
and peptides fused to a vault targeting domain are packaged in the
particle, protected from the external environment and released
slowly. This is the first study to describe that vault nanocapsules
can be engineered to package and retain biologically active
CCL21. Our results demonstrate that although empty vaults and
rCCL21 are each chemotactic, packaging the chemokine into
vault synergistically enhanced T cell migration, suggesting that the
sustained release of CCL21 by the vault particle can establish a
steep chemotatic gradient. Neutralizing antibodies to CCL21
abrogated the chemotactic activity of the CCL21-vault demon-
strating that the chemotactic activity was predominantly CCL21
dependent. Based on the results of chemotactic experiments, we
evaluated the impact of CCL21-vaults on DC APC activity.
CCL21-vaults augmented DC APC activity and neutralization of
CCL21 abrogated this activity. In comparison to rCCL21,
CCL21-vaults stimulated DC APC activity to greater levels at
one tenth the concentration of rCCL21, suggesting a greater DC
affinity for the CCL21-vault nanocapsule.
Based on our in vitro findings, CCL21-vaults were evaluated in a
therapeutic lung cancer model in vivo. Our results demonstrate that
the vault design is effective at inhibiting the growth of established
tumors. A single intratumoral injection of CCL21-vaults led to
significant inhibition in tumor growth compared to controls. Our
data suggests that the CCL21-vault formulation is as effective in
comparison to the frequent high doses of rCCL21 [13]. In both
the subcutaneous and orthotopic lung tumor models the CCL21-
vault therapy was administered intratumorally. In future studies
when evaluating the efficacy of tumor antigen specific vault
nanocaspsules vaccination routes in the protective and therapeutic
settings that include i.v or i.p. delivery routes, changes in plasma/
serum transaminase level will be quantified for vault effects on
Figure 3. Intratumoral CCL21-vaults reduce tumor growth and
enhance T cell leukocytic infiltrates. A. CCL21-vaults inhibited
tumor growth and enhanced intratumoral T cell infiltrates in lung
cancer. C57BL/6 mice bearing 9 day 3LL established tumors (s.c.) were
treated intratumorally with control vaults (200 ng), mCCL21-vaults
(200 ng) or diluent normal saline (NS). Bisecting tumor diameters were
measured with calipers. B–C. mCCL21-vaults increased the influx of CD3
expressing T cells in the tumor as compared to control vaults. UBC-GFP/
BL6 mice bearing 9-day established tumors were treated intratumorally
with control vaults or mCCL21-vaults. OCT frozen tissue was sectioned,
fixated onto slides, and counterstained with the nuclear dye DAPI
(blue). Control tumors (top panel) demonstrate very limited green
fluorescence (infiltrating cells) under a high-power view (magnification,
6400). Most green fluorescent cells are large polygonal stromal cells
while tumor cells are counterstained blue by DAPI. Immune staining for
T cells shows very few CD3 expressing T lymphocytes (top right panel).
In contrast, prominent tumor-infiltrating lymphocytes, small round
green fluorescent cells are evident in tumors from the mCCL21-vault-
treated mice (arrow, bottom panel). Immune staining for T cells shows
that the infiltrates are CD3 expressing T cells (bottom right). Data; Mean
6 SEM, *p,0.05 between mCCL21-vault and control group, n=10
mice/group.
doi:10.1371/journal.pone.0018758.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e18758liver function. Although in the migration assay, the control vaults
demonstrated chemotactic activity, control vaults did not affect
tumor growth compared to the diluents treatment group. This
suggests that CCL21 is the critical component in the vault
nanocapsule for the induction of antitumor activity. In future work
we will screen both the pro-apoptotic and anti-apoptotic proteins
in the tumors to determine changes in response to CCL21-vault
nanocapsule therapy to mechanistically explore the apoptotic
programs induced by this therapy. In vivo, human CCL21
containing vaults were as effective as the murine CCL21-vault in
reducing 3LL tumor growth (data not shown). In comparison to
controls, CCL21-vault treatment resulted in extensive tumor T
and DC leukocytic infiltrates. Intratumoral infiltration by elevated
frequencies of T lymphocytes [31,32] and APC [33] in lung cancer
is associated with a better patient outcome. There was an
increased IFNc and reduced IL-10 cytokine signature of T
lymphocytes infiltrating the tumors of CCL21-vault treated mice.
Based on our previous observations with rCCL21 in preclinical
models [13], the increased frequency of T cell subsets (CD4 and
CD8), CXCR3 and CCR7 expressing T cell effectors and DC in
the lung tumor microenvironment is beneficial and most probably
responsible for enhanced antitumor activity of CCL21-vaults. In a
recent study, Dieu-Nosjean et al. [33] retrospectively identified
ectopic lymph node or tertiary lymphoid structures within human
non-small cell lung cancer specimens and demonstrated a
correlation of the cellular content with clinical outcomes. The
density of DC-Lamp+, mature DC within these structures was a
predictor of long-term survival in the selected lung cancer patient
population. The authors observation that a low density of tumor-
infiltrating CD4
+ and T-bet
+T lymphocytes were present in
tumors poorly infiltrated by DCLamp
+ mature DC provides
additional supportive evidence for the prognostic importance of an
adaptive immune reaction to a solid tumor [33]. In the present
study we do not know if the involvement of CD1d-mediated
antigen presentation to NKT cells contributes to the antitumor
activity of CCL21-vault nanocapsules. However since NKT cells
express the CCR7 receptor, future work will delineate their role in
CCL21-vault nanocapsule mediated antitumor reactivity.
Immune suppression has a crucial role in promoting tumor
progression. Treg and MDSC contribute to immune suppression
in the tumor bearing host. Although T cells accumulate in lung
cancer tissues they fail to respond because a high proportion of
tumor infiltrating lymphocytes (TIL) are Tregs [34,35]. Treg cells
actively down regulate the activation and expansion of antitumor
reactive T cells [36,37,38] and NK cells [39]. In addition to Tregs,
MDSC have a strong suppressive activity in cancer patients
[40,41,42,43] and tumor-bearing mice [44,45,46]. These immune
suppressive cells inhibit T cell [47,48] and NK cell activity [49,50]
and pose a significant hurdle to successful immune based therapy.
The reduction in these immune suppressor phenotypes may
enhance immune based anti tumor approaches. We found that in
comparison to controls, CCL21-vault therapy group had reduced
the frequencies of Treg and MDSC and systemically enhanced T
lymphocytic lysis of parental tumor cells. Thus the benefit of
utilizing CCL21-vaults is the recruitment and activation of
antitumor effectors and reduced frequencies of Treg and MDSC
immune suppressors.
Our combined results indicate that the CCL21-vault nanocap-
sule platform is an effective antitumor strategy. This holds
significance for broad application as an off the shelf reagent for
cancer therapy. We have demonstrated that vault nanoparticles
containing the major outer membrane protein of Chlamydia,
could be delivered to the respiratory tract, by the intranasal route
and induced robust anti-chlamydial immune responses [7]. The
addition of EGF onto the outside of vault particles can be used to
specifically target cells expressing high levels of EGFR and leads to
phosphorylation of Tyr1173 on the receptor [30]. This suggests
that vault particles can be designed as multifunctional vehicles that
can be further engineered for target specific delivery as well as
carriers of specific payloads that can act as tumor antigens to
prime the immune system to potentially act as vaccines to prevent
tumor recurrence and metastasis. These multifunctional nanopar-
ticles may prove indispensable as cancer therapeutics. The results
of our study are encouraging and warrant further evaluation of the
vault nanocapsule delivery platform for its full therapeutic
potential in lung cancer and other malignancies.
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